Skip to content
Catalyst

PapersPMID:30835327

Effect of coenzyme Q10 in Europeans with chronic heart failure: A sub-group analysis of the Q-SYMBIO randomized double-blind trial.

Cardiology journal2019The record ↗

  1. Finding, moderate evidencelowersAll-cause mortality

What moved

1 findingHow to read these marks →
  • “All-cause mortality was lower in the CoQ10 group, 10 (9%) patients vs. 24 (20%) patients in the placebo group, corresponding to a relative reduction of 53% (p = 0.040).”
    Study
    RCT
    Dose studied
    CoQ10 (Ubiquinone) 300 mg/day added to standard heart failure therapy
    Population
    European sub-population (n=231) of the Q-SYMBIO trial, moderate-to-severe chronic heart failure, on standard HF therapy in both arms, long-term (2-year) follow-up

Study record

Design
randomised controlled trial
Species
human
Population
European sub-population of Q-SYMBIO with moderate to severe heart failure
Participants
231
Comparator
placebo
Duration
731 days
Endpoints measured
39